Palvella Therapeutics is a start-up life sciences company in Pennsylvania that focuses on serving abandoned patient populations with therapies. Founded 2015 in Wayne, Pennsylvania, United States by Wes Kaupinen, Palvella Therapeutics has raised a total of $59.4M in funding over four rounds. Their latest funding was raised on May 28, 2020 from a series C round. Palvella Therapeutics is funded by 10 investors, with Opaleye Management and BioAdvance are the most recent investors. The company is engaged in developing novel, disease-modifying therapies to treat pachyonychia congenita, an ultra-orphan and chronically-debilitating genetic disease for which no treatments currently exist. These treatments enable patients to get the best treatment for diseases and lead a better life.
Derived from the Finnish word for "to serve", Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments. By developing pathogenetically targeted therapies that address the root causes of these diseases, we believe we can dramatically enhance quality of life.
